Active, not recruitingPhase 2NCT02396459
Triac Trial II in MCT8 Deficiency Patients
Studying Allan-Herndon-Dudley syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rare Thyroid Therapeutics International AB
- Principal Investigator
- W.E. Visser, MD, PhDErasmus Medical Center
- Intervention
- Tiratricol(drug)
- Enrollment
- 22 enrolled
- Eligibility
- MALE
- Timeline
- 2020 – 2027
Study locations (5)
- Oregon Health & Science University (OHSU) Doernbecher Childrens Hospital, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Charles University and Motol University Hospital; The department of peadiatrics of the 2nd faculty of medicine, Prague, Czechia
- Charité - Universitätsmedizin Berlin Institut fur experimental paediatrische endokrinologie, Berlin, Germany
- Erasmus MC, Rotterdam, Netherlands
Collaborators
Erasmus Medical Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02396459 on ClinicalTrials.govOther trials for Allan-Herndon-Dudley syndrome
Additional recruiting or active studies for the same condition.